BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT00516451
- Locations
- 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00514371
- Locations
- 🇺🇸
Local Institution, Columbia, South Carolina, United States
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00508287
- Locations
- 🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
- Conditions
- SchizophreniaMetabolic Syndrome
- Interventions
- Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 125
- Registration Number
- NCT00508157
- Locations
- 🇹🇷
Local Institution, Izmir, Turkey
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6421
- Registration Number
- NCT00496769
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Kaiser Permanente Medical Center, West Los Angeles, Los Angeles, California, United States
🇺🇸Southwest Heart, Tucson, Arizona, United States
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
- Conditions
- Melanoma
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00495066
- Locations
- 🇧🇷
Instituto ÉTICA - AMO - Assistência Multidisciplinar em Oncologia, Salvador, Bahia, Brazil
🇧🇷Hospital Sao Jose - Beneficencia Portuguesa - Oncology Center, Sao Paulo, SP, Brazil
🇧🇷Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
- Conditions
- Antiplatelet Aggregation
- Interventions
- Procedure: Blood Collection
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 103
- Registration Number
- NCT00493779
- Locations
- 🇬🇧
Local Institution, Southampton, Hampshire, United Kingdom
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 217
- Registration Number
- NCT00484289
- Locations
- 🇯🇵
Local Institution, Chiba-Shi, Japan
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT00482703
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 547
- Registration Number
- NCT00481247
- Locations
- 🇺🇸
Molecular Md, Portland, Oregon, United States
🇹🇷Local Institution, Kayseri, Turkey